Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ponatinib · Iclusig, AP-24534

Small molecule · Inhibitor of ABL1 tyrosine kinase (BCR::ABL fusion kinase) (ABL1) · developed by Takeda Pharms Usa

Approved FDA, Dec 2012
TAK Developer
2 Registered trials

What is Ponatinib?

Ponatinib is an orally available multitargeted kinase inhibitor that binds the BCR::ABL fusion kinase, including the T315I mutant form, and also inhibits VEGFR, FGFR, PDGFR, TIE2, FLT3, KIT and RET kinases. It is studied in Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Iclusig, AP-24534, Iclusig, INCB84344
Drug type
Small molecule
Targets
ABL1 tyrosine kinase (BCR::ABL fusion kinase) (ABL1), VEGFR family receptors (secondary target), FGFR family receptors (secondary target), PDGFR family receptors (secondary target), TIE2 receptor (TEK) (secondary target), FLT3 (secondary target)
Mechanism
Inhibitor of ABL1 tyrosine kinase (BCR::ABL fusion kinase) (ABL1)
Pathways
BCR::ABL kinase signaling, angiogenesis
Therapy area
Oncology
Developer
Takeda Pharms Usa (TAK)
Also in trials of
AMGN, INCY
FDA status
Approved as Iclusig (December 14, 2012), NDA203469 · FDA label
UNII
4340891KFS

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03934372 Phase 1/2 Acute Myeloid Leukemia Recruiting INCY
NCT03263572 Phase 2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Accelerated Phase Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid LeukemiaLeukemiaLymphomaPhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemiat(9;22)

Other drugs acting on ABL1

More from Takeda Pharms Usa

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Ponatinib

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.